Wiser Healthcare, Sydney School of Public Health, The University of Sydney, Sydney, 2006, NSW, Australia.
Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), The University of Sydney, Sydney, 2006, NSW, Australia.
BMC Cancer. 2018 Mar 2;18(1):242. doi: 10.1186/s12885-018-4152-9.
In recent years management practices in relation to low-risk papillary microcarcinoma (PMC) have been evolving with increased awareness of the potential overdiagnosis and overtreatment of PMCs, and guidelines recommendations for non-surgical management options such as active surveillance. This study aimed to develop an in-depth understanding of patients' experiences of the communication of their PMC diagnosis, their treatment preferences and decision making.
Semi-structured qualitative interviews with 25 patients diagnosed pre-operatively with PMC < 1 year since their diagnosis and treatment. Interviews were conducted between September 2015 and July 2016 and were audio-recorded and transcribed verbatim. Framework analysis method was used to analyse the data.
The diagnosis and treatment experience of PMC patients varied widely. The majority of patients were asymptomatic, and their PMC was initially detected via an imaging test requested for a reason unrelated to a thyroid disorder or symptom. Clinicians generally described PMC to patients as being a "small" or "slow-growing" cancer, and there was little evidence that clinicians had discussions about the possibility of overdiagnosis or overtreatment. Overall, surgery was the only option discussed and offered to patients. Patients preference for treatment was largely based on eliminating the possibility of the cancer spreading (thyroidectomy) or not wanting to be on thyroid replacement medication for the rest of their life (hemi-thyroidectomy). Many patients reported emotional and physical side-effects associated with their diagnosis and treatment, however patients generally indicated that active surveillance is not something they would have been interested in if it was offered to them.
Evidence continues to emerge that many patients with PMCs may be overdiagnosed, and management guidelines are recommending more conservative management options for these patients. As a result, shared decision making around treatment options is vital so that patients are fully aware of the meaning of their diagnosis and their management options including active surveillance. Importantly, interventions to reduce unnecessary diagnoses of PMC are critically needed.
近年来,随着人们对低危型甲状腺微小乳头状癌(PMC)过度诊断和过度治疗的潜在风险的认识不断提高,以及对主动监测等非手术治疗选择的指南推荐,与 PMC 相关的管理实践也在不断发展。本研究旨在深入了解患者对其 PMC 诊断的沟通、治疗偏好和决策的体验。
对 25 名患者进行半结构化定性访谈,这些患者在诊断前被诊断为 PMC <1 年,并且在诊断和治疗后 <1 年。访谈于 2015 年 9 月至 2016 年 7 月进行,录音并逐字记录。采用框架分析法对数据进行分析。
PMC 患者的诊断和治疗经历差异很大。大多数患者无症状,其 PMC 最初是通过与甲状腺疾病或症状无关的影像学检查发现的。临床医生通常将 PMC 描述为“小”或“生长缓慢”的癌症,几乎没有证据表明临床医生曾讨论过过度诊断或过度治疗的可能性。总的来说,手术是唯一与患者讨论和提供的选择。患者对治疗的偏好主要基于消除癌症扩散的可能性(甲状腺切除术)或不想在余生中服用甲状腺替代药物(半甲状腺切除术)。许多患者报告了与诊断和治疗相关的身体和情绪副作用,但患者普遍表示,如果向他们提供主动监测,他们不会感兴趣。
越来越多的证据表明,许多 PMC 患者可能被过度诊断,管理指南建议对这些患者采用更保守的治疗选择。因此,围绕治疗选择进行共同决策至关重要,以使患者充分了解其诊断的含义及其管理选择,包括主动监测。重要的是,迫切需要采取干预措施减少不必要的 PMC 诊断。